Zobrazeno 1 - 10
of 215
pro vyhledávání: '"Uncommon EGFR mutations"'
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 5503-5510 (2024)
Xiang Han,1 Yunhong You,1 Xiuhui Guo,2 Youxin Ji,1 Keke Nie1 1Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, 266042, People’s Republic of China; 2Department of
Externí odkaz:
https://doaj.org/article/a4bc11e53e974b5dbabf473041dc81f1
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 69-73 (2024)
Faustine X Luo,1,2 Sai-Hong Ignatius Ou1,2 1Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USA; 2University of California Irvine School of Medicine, Orange, CA, 92868, USACorrespondence: Sai-Hong Ignatius Ou, University of California Irv
Externí odkaz:
https://doaj.org/article/7977f3d48c1f49229c8e7aea481cdcf7
Autor:
Kaiyan Chen, Yanjun Xu, Zhiyu Huang, Xiaoqing Yu, Wei Hong, Hui Li, Xiaoling Xu, Hongyang Lu, Fajun Xie, Jun Chen, Youzu Xu, Yun Fan
Publikováno v:
Cancer Medicine, Vol 12, Iss 19, Pp 19460-19470 (2023)
Abstract Background Patients with non‐small‐cell lung cancer (NSCLC) and uncommon EGFR alterations typically have worse treatment outcomes than patients with classically EGFR‐mutated NSCLC. This study aimed to investigate the efficacy and safet
Externí odkaz:
https://doaj.org/article/ae2a1ab341eb4cffae94d7451f3db4c0
Autor:
Chen Shi, Cong Zhang, Zhiwen Fu, Jinmei Liu, Yuanfeng Zhou, Bao Cheng, Cong Wang, Shijun Li, Yu Zhang
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 13, Iss 6, Pp 2613-2627 (2023)
Uncommon epidermal growth factor receptor (EGFR) mutations account for 10%–20% of all EGFR mutations in non-small-cell lung cancer (NSCLC). The uncommon EGFR-mutated NSCLC is associated with poor clinical outcomes and generally achieved unsatisfact
Externí odkaz:
https://doaj.org/article/042083c0f0b24c0e8de95297a5585825
Autor:
Ya Zeng, Tiantian Guo, Yue Zhou, Yang Zhao, Li Chu, Xiao Chu, Xi Yang, Jianjiao Ni, Zhengfei Zhu
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background The clinical features, survival outcomes and patterns of treatment failure of advanced non-small cell lung cancer (NSCLC) patients harboring distinct subtypes of EGFR mutations and receiving first-line EGFR tyrosine kinases inhibi
Externí odkaz:
https://doaj.org/article/d08bf5f87f2a4718a4e3b5c148098c89
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAfatinib is a potent, irreversible second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has demonstrated efficacy in advanced non-small cell lung cancer (NSCLC) patients harboring either common or uncomm
Externí odkaz:
https://doaj.org/article/c1b60c683cf544b79e7fb36c292fcdb6
Autor:
Vito Longo, Annamaria Catino, Michele Montrone, Pamela Pizzutilo, Francesco Pesola, Ilaria Marech, Iolanda Capone, Arsela Prelaj, Domenico Galetta
Publikováno v:
Thoracic Cancer, Vol 12, Iss 13, Pp 2031-2034 (2021)
Abstract Patients with non‐small cell lung cancer (NSCLC) and uncommon epidermal growth factor receptor (EGFR) mutation are characterized by high heterogeneity, and globally considered to have a worse prognosis than patients with the two common mut
Externí odkaz:
https://doaj.org/article/35e214ab38604b83854e2e888b4bfc36
Publikováno v:
Global Medical Genetics, Vol 08, Iss 04, Pp 171-175 (2021)
Background The quality programs can be considered to be a valuable tool for global and individual growth. Each result, obtained by a single laboratory, contributes to define the standardization of the response. In the case of the uncommon epidermal g
Externí odkaz:
https://doaj.org/article/db65eb245f784111913ef238de4903be
Autor:
Hong-Shuai Li, Guang-Jian Yang, Yi Cai, Jun-Ling Li, Hai-Yan Xu, Tao Zhang, Li-Qiang Zhou, Yu-Ying Wang, Jin-Liang Wang, Xing-Sheng Hu, Xiang Yan, Yan Wang
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical evidence of its activity on major uncommon EGFR mutations is currently l
Externí odkaz:
https://doaj.org/article/a0304755a1dc4eaf9b7018977d22936b
Autor:
Chengyang Song, Xueying Yang
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Osimertinib is a third-generation, irreversible mutant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Osimertinib is currently the
Externí odkaz:
https://doaj.org/article/cdd7ad1e94ae4b97b9dc6f62117b723e